Article
Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes.
The Lancet. Oncology - 1 Dec 2021
Thariat Juliette, Chevalier Francois, Orbach Daniel, Ollivier Luc, Marcy Pierre-Yves, Corradini Nadege, Beddok Arnaud, Foray Nicolas, Bougeard Gaelle
Abstract excerpt
The management of patients with cancer and Li-Fraumeni or heritable TP53-related cancer syndromes is complex because of their increased risk of developing second malignant neoplasms after genotoxic stresses such as systemic treatments or radiotherapy (radiosusceptibility). Clinical decision making also integrates the risks of normal tissue toxicity and sequelae (radiosensitivity) and tumour response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
